OBJECTIVE: Glucocerebrosidase (GBA) gene mutations represent a strong risk factor for Parkinson disease (PD). PD penetrance in GBA mutation carriers, which represents a key issue for genetic counseling, especially for relatives of patients with Gaucher disease (GD), is unknown. Our objective was to estimate PD penetrance in a familial study of GBA mutation carriers. METHODS: Probands with familial PD were recruited through the French Parkinson Disease Genetic Study Group. All GBA exons were sequenced in probands and their relatives. To estimate the age-specific cumulative PD risk (i.e., penetrance) in GBA mutation carriers, we used the proband's phenotype exclusion likelihood method and corrected for selection of familial cases by considering the status of one affected relative per family as unknown. RESULTS: Of 525 probands with familial PD, 24 (4.6%) were GBA mutation carriers. Of their 256 relatives, 43 (16.8%) had PD and 26 of 32 affected relatives tested for GBA mutations were mutation carriers; 213 relatives did not have PD and 31 of 71 of unaffected relatives tested for GBA mutations were mutation carriers. Under a dominant model, penetrance was estimated as 7.6%, 13.7%, 21.4%, and 29.7% at 50, 60, 70, and 80 years, respectively. There was no significant difference in penetrance at 70 years between N370S carriers, L444P carriers, and carriers of rarer mutations. CONCLUSION: The relatively high penetrance estimate in GBA carriers obtained in this study should lead to consideration of GBA as a dominant causal gene with reduced penetrance and should be taken into account for genetic counseling in relatives of patients with GD and patients with GBA-associated PD.
OBJECTIVE:Glucocerebrosidase (GBA) gene mutations represent a strong risk factor for Parkinson disease (PD). PD penetrance in GBA mutation carriers, which represents a key issue for genetic counseling, especially for relatives of patients with Gaucher disease (GD), is unknown. Our objective was to estimate PD penetrance in a familial study of GBA mutation carriers. METHODS: Probands with familial PD were recruited through the French Parkinson Disease Genetic Study Group. All GBA exons were sequenced in probands and their relatives. To estimate the age-specific cumulative PD risk (i.e., penetrance) in GBA mutation carriers, we used the proband's phenotype exclusion likelihood method and corrected for selection of familial cases by considering the status of one affected relative per family as unknown. RESULTS: Of 525 probands with familial PD, 24 (4.6%) were GBA mutation carriers. Of their 256 relatives, 43 (16.8%) had PD and 26 of 32 affected relatives tested for GBA mutations were mutation carriers; 213 relatives did not have PD and 31 of 71 of unaffected relatives tested for GBA mutations were mutation carriers. Under a dominant model, penetrance was estimated as 7.6%, 13.7%, 21.4%, and 29.7% at 50, 60, 70, and 80 years, respectively. There was no significant difference in penetrance at 70 years between N370S carriers, L444P carriers, and carriers of rarer mutations. CONCLUSION: The relatively high penetrance estimate in GBA carriers obtained in this study should lead to consideration of GBA as a dominant causal gene with reduced penetrance and should be taken into account for genetic counseling in relatives of patients with GD and patients with GBA-associated PD.
Authors: M J Barrett; V L Shanker; W L Severt; D Raymond; S J Gross; N Schreiber-Agus; R Kornreich; L J Ozelius; S B Bressman; R Saunders-Pullman Journal: JIMD Rep Date: 2014-05-22
Authors: Chris M Woodard; Brian A Campos; Sheng-Han Kuo; Melissa J Nirenberg; Michael W Nestor; Matthew Zimmer; Eugene V Mosharov; David Sulzer; Hongyan Zhou; Daniel Paull; Lorraine Clark; Eric E Schadt; Sergio Pablo Sardi; Lee Rubin; Kevin Eggan; Mathew Brock; Scott Lipnick; Mahendra Rao; Stephen Chang; Aiqun Li; Scott A Noggle Journal: Cell Rep Date: 2014-11-06 Impact factor: 9.423
Authors: Roy N Alcalay; Tama Dinur; Timothy Quinn; Karina Sakanaka; Oren Levy; Cheryl Waters; Stanley Fahn; Tsvyatko Dorovski; Wendy K Chung; Michael Pauciulo; William Nichols; Huma Q Rana; Manisha Balwani; Louise Bier; Deborah Elstein; Ari Zimran Journal: JAMA Neurol Date: 2014-06 Impact factor: 18.302
Authors: Laurie A Robak; Iris E Jansen; Jeroen van Rooij; André G Uitterlinden; Robert Kraaij; Joseph Jankovic; Peter Heutink; Joshua M Shulman Journal: Brain Date: 2017-12-01 Impact factor: 13.501
Authors: M J Barrett; P Giraldo; J L Capablo; P Alfonso; P Irun; B Garcia-Rodriguez; M Pocovi; G M Pastores Journal: J Inherit Metab Dis Date: 2012-09-12 Impact factor: 4.982